No services found
No Products found
Are low antibody yields stopping you from reaching the market? Improve the odds of monoclonal antibody development success by choosing a stable cell line development platform focused on developability. Drawing from 30 years of experience in protein production and over 100 stable cell lines generated, our pipeline offers high and stable yields tied to the market’s strongest guarantees. Monoclonal antibody production made simple with our CMO-transferrable FTO cell lines with high-yields (>7g/L) at competitive prices.
FTO cell lines
Benefit from our royalty-free approach to speed up clinical development.
Ease of transference
Fast cell line and protocol transference to your CMO partners for cGMP bioproduction.
Emphasis on developability
Minimize production risks thanks to our extensive early testing of antibody candidates.
Cell line diversity
Proprietary CHO, CHO-S, CHO-DG44, HEK293 or even your preferred cell line… Get a service adapted to your requirements!
Ensure your cell line generates the highest possible yields thanks to our proven amplification protocols.
Plan for the long-term and secure your investments by choosing a stable cell line development service with strong guarantees.
Protein production experts
500+ monoclonal antibodies developed, 100+ stable cell lines generated, 28+ years of experience in protein production. Choose a leading bioproduction company.
Full process control
Stay in complete control of your project thanks to our milestone-oriented approach for better flexibility.
Expression vector construction
Host transfection and selection of positive pools
Isolation of the best monoclones
Characterization of the best monoclones
Stable cell line and protocol transference
After stable cell line development:
Chinese hamster ovary (CHO) cell lines
CHO-S, CHO-DG44, CHO-K1, proprietary GS-CHO cell line (upcoming) among others
Human embryonic kidney (HEK) cell lines
HEK293F, HEK293E, among others
Customer-provided cell lines
Baby hamster kidney (BHK), mouse myeloma (NS0) cells, Per.C6, among others
Most mammalian cell lines can either be selected using metabolic or antibiotic markers. The most widely used markers for recombinant monoclonal antibody production are metabolic, including:
Metabolic selection markers have remained the gold standard for stable cell line generation. This preference can be explained by the versatility of these systems. Particularly in CHO cells, the presence of increasing concentrations of MTX/MSX is unknown to result in the amplification of antibody encoding genes. Consequently, this leads to a significant increase in production yield in comparison to other recombinant expression systems.
However, our focus remains on flexibility. For this reason we offer a vast choice of selection systems and cell lines allowing us to adapt the process of stable cell line generation to your unique requirements and needs.
Discuss your project with our PhD account managers to receive a tailor-made proposal:
Antibody genes were optimized for expression in CHO cell lines, synthesized, and subcloned into our proprietary transient expression system.
CHO-K1 cells (30 ml) were transiently transfected, transient pools were grown in 30 ml, and antibody purification was performed using protein G resin.
3 positive stable pools were further characterized in fed-batch experiments and antibodies characterized by SEC-HPLC to confirm purity and detect potential aggregation
Monoclones were isolated using the limiting dilution method in 96-well plates and
expression evaluation was performed by ELISA with anti-Fc antibodies
2 Rounds of limiting dilution
29 Best performing clones
Best monoclones were evaluated by SDS-PAGE and ELISA (Fc-antibody).
ELISA data (below) revealed 10 monoclones with high expression levels.
Bar length represents intensity obtained in ELISA, numbers represent the clone ID.
Monoclones 3, 10, 17, and 19 maintained good stability and viability in
subsequent tests and were selected for further development
Monoclone 10 was used for initial scale-up with excellent results.
95% of biologics under development fail to reach the market or clinic due to undetected developability issues. Early testing or screening has thus become crucial to overcome low success rates and minimize development risks. Producing monoclonal antibodies in vitro via transient systems is still the best way to produce small amounts of antibodies for measuring:
Detectable problems at this stage can be corrected by additional engineering of antibody leads. These engineering efforts, although laborious, can save considerable costs and time on the long run to license your therapeutic antibodies.
To learn more about stable cell line development, visit our frequently asked questions (FAQs) page. On this page, we cover all seminal principles and knowledge regarding monoclonal antibody production in stable cells and provide detailed insights into ProteoGenix’s unique platform for stable cell line development.
Got a question or need a quote? Message us and we'll get back to you 48 hours or less.
Your cart is currently empty.